GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES–(BUSINESS WIRE)–$GOSS—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Gossamer announced on February 23, 2026, that its product candidate seralutinib failed to meet its primary endpoint in the Phase 3 PROSERA trial. Based on this news, shares of Gossamer fell more than 80.1% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contacts

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com